Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial
Wuhan University · Zhongnan Hospital of Wuhan University · +4 more institutions
Abstract
This randomized phase III study was to evaluate the efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal carcinomatosis (PC) from gastric cancer.
Sixty-eight gastric PC patients were randomized into CRS alone (n = 34) or CRS + HIPEC (n = 34) receiving cisplatin 120 mg and mitomycin C 30 mg each in 6000 ml of normal saline at 43 ± 0.5°C for 60-90 min. The primary end point was overall survival, and the secondary end points were safety profiles.
Citation impact
- FWCI
- 32.89
- Percentile
- 100%
- References
- 28
Authors
10- XYXiaojun YangCorresponding
Wuhan University, Zhongnan Hospital of Wuhan University
- CHChaoqun Huang
Zhongnan Hospital of Wuhan University, Wuhan University
- TSTao Suo
Zhongshan Hospital, The First Affiliated Hospital, Sun Yat-sen University, Fudan University, Sun Yat-sen University
- LMLie-Jun Mei
Wuhan University, Zhongnan Hospital of Wuhan University
- GYGuoliang Yang
Wuhan University, Zhongnan Hospital of Wuhan University
Topics & keywords
- Medicine
- Hyperthermic intraperitoneal chemotherapy
- Surgical oncology
- Randomized controlled trial
- Surgery
- Peritoneal carcinomatosis
- Confidence interval
- Clinical endpoint
- Good health and well-being